What one share of Skye Bioscience holds
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.
Skye Bioscience’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.27 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.98 |
| Cash and investments | $0.23 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$66.42 | $0.57 | −$43.20 | — | −$7.09 |
| 2015 | — | −$71.45 | $0.03 | −$55.05 | — | −$11.21 |
| 2016 | — | −$41.93 | $0.15 | −$47.03 | — | −$33.79 |
| 2017 | — | −$27.72 | $0.18 | −$30.02 | — | −$26.54 |
| 2018 | — | −$39.61 | $0.01 | −$8.15 | — | −$29.05 |
| 2020 | — | −$7.46 | $0.01 | −$6.55 | — | $0.39 |
| 2021 | — | −$5.00 | $0.06 | −$4.04 | — | $3.08 |
| 2022 | — | −$8.77 | $0.01 | −$5.75 | — | −$0.82 |
| 2023 | — | −$5.37 | $0.00 | −$1.99 | — | −$0.17 |
| 2024 | — | −$0.73 | $0.04 | −$0.74 | — | $2.20 |
| 2025 | — | −$1.41 | $0.00 | −$1.09 | — | $0.60 |
Common questions about Skye Bioscience
How much does one share of Skye Bioscience earn?
Over the last 12 months, Skye Bioscience lost $1.27 for each share.
Does Skye Bioscience pay a dividend?
Skye Bioscience didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Skye Bioscience’s book value per share?
Skye Bioscience’s book value is negative (−$0.01 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Skye Bioscience have?
Each share of Skye Bioscience has $0.23 of cash and investments, as of June 30, 2026.
What is Skye Bioscience’s free cash flow per share?
−$0.98 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Skye Bioscience bought back shares?
Skye Bioscience’s share count rose about 96245% from 2014 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.